High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo
Authors:
- Annika LehmannALAnnika Lehmann
- Carsten DenkertCDCarsten Denkert
- Jan BudcziesJBJan Budczies
- Ann-Christin BuckendahlABAnn-Christin Buckendahl
- Silvia Darb-EsfahaniSDSilvia Darb-Esfahani
- Aurelia NoskeANAurelia Noske
- Berit Maria MüllerBMBerit Maria Müller
- Marcus BahraMBMarcus Bahra
- Peter NeuhausPNPeter Neuhaus
- Manfred DietelMDManfred Dietel
- Glen KristiansenGKGlen Kristiansen
- Wilko WeichertWWWilko Weichert
Open Access
- 13 November 2009
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 1-10
Abstract
The strong association between aberrant HDAC activity and the occurrence of cancer has led to the development of a variety of HDAC inhibitors (HDIs), which emerge as promising new targeted anticancer therapeutics. Due to the pivotal role of RelA/p65 in the tumorigenesis of pancreatic neoplasia we examined the expression of class I HDACs 1, 2 and 3 in a large cohort of human pancreatic carcinomas and correlated our findings with RelA/p65 expression status. Furthermore, we investigated the impact of the HDIs SAHA and VPA on RelA/p65 activity in pancreatic cancer cell culture models. Class I HDACs were strongly expressed in a subset of pancreatic adenocarcinomas and high expression was significantly correlated with increased nuclear translocation of RelA/p65 (p = 0.024). The link of HDAC activity and RelA/p65 in this tumor entity was confirmed in vitro, where RelA/p65 nuclear translocation as well as RelA/p65 DNA binding activity could be markedly diminished by HDI treatment. The RelA/p65 inhibitory effects of SAHA and VPA in vitro and the close relationship of class I HDACs and RelA/p65 in vivo suggest that treatment with HDIs could serve as a promising approach to suppress NF-κB activity which in turn may lead to enhanced apoptosis and chemosensitization of pancreatic cancers.Keywords
This publication has 35 references indexed in Scilit:
- Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivoClinical Cancer Research, 2008
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysisThe Lancet Oncology, 2008
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomyBritish Journal of Cancer, 2008
- High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosisBritish Journal of Cancer, 2007
- Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugNature Biotechnology, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Histone Deacetylase Inhibition Down-Regulates Cyclin D1 Transcription by Inhibiting Nuclear Factor-κB/p65 DNA BindingMolecular Cancer Research, 2005
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002